Angelman Syndrome Market

Aug 07, 2020

10 likes | 62 Views

The total prevalent cases of Angelman Syndrome in the seven major markets was 57,716 in 2017. Among the 7MM, the prevalence of Angelman Syndrome in the United States and Germany were found to be 21,715 and 6,448 respectively in 2017. The therapeutic market of Angelman Syndrome in the 7MM was USD 255 Million in 2017, which is expected to increase during the forecast period 2017-2030. Biomarker studies, increasing prevalence of Angelman Syndrome, and molecular level diagnosis are some of the key factors expected to drive the Angelman Syndrome market forward in the coming years. The key players in the Angelman Syndrome market include Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics and many others. For more details on Angelman Syndrome Market visit: https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast angelman-syndrome-market-Size-and-share-analysis #geneticdisorder #raredisease #neurogeneticdisorder #neurogenetic #neurogenetic #nervoussystem

DelveInsight

Download Presentation

Angelman Syndrome Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D